Richard F Olsson
Overview
Explore the profile of Richard F Olsson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
1506
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jimenez Jimenez A, de Lima M, Komanduri K, Wang T, Zhang M, Chen K, et al.
Bone Marrow Transplant
. 2022 Mar;
57(5):852.
PMID: 35297406
No abstract available.
2.
Jimenez Jimenez A, de Lima M, Komanduri K, Wang T, Zhang M, Chen K, et al.
Bone Marrow Transplant
. 2021 Sep;
56(12):3068-3077.
PMID: 34584240
Cytogenetic and molecular abnormalities are known to influence post-transplant outcomes in acute myeloid leukemia (AML) but data assessing the prognostic value of combined genetic models in the HCT setting are...
3.
Wieduwilt M, Metheny L, Zhang M, Wang H, Estrada-Merly N, Marks D, et al.
Blood Adv
. 2021 Sep;
6(1):339-357.
PMID: 34547770
The role of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariable analysis comparing outcomes of HCT...
4.
Metheny L, Callander N, Hall A, Zhang M, Bo-Subait K, Wang H, et al.
Transplant Cell Ther
. 2021 Aug;
27(11):923.e1-923.e12.
PMID: 34428556
Patients who develop therapy-related myeloid neoplasm, either myelodysplastic syndrome (t-MDS) or acute myelogenous leukemia (t-AML), have a poor prognosis. An earlier Center for International Blood and Marrow Transplant Research (CIBMTR)...
5.
Oran B, Ahn K, Fretham C, Beitinjaneh A, Bashey A, Pawarode A, et al.
Transplant Cell Ther
. 2021 Aug;
27(11):921.e1-921.e10.
PMID: 34403791
Reduced-intensity conditioning (RIC) regimens developed to extend the use of allogeneic hematopoietic stem cell transplantation (HSCT) to older patients have resulted in encouraging outcomes. We aimed to compare the 2...
6.
Lazaryan A, Dolan M, Zhang M, Wang H, Kharfan-Dabaja M, Marks D, et al.
Haematologica
. 2021 Aug;
106(8):2295-2296.
PMID: 34333962
No abstract available.
7.
Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, et al.
Leukemia
. 2021 Jun;
35(7):2141.
PMID: 34091601
No abstract available.
8.
Percival M, Wang H, Zhang M, Saber W, de Lima M, Litzow M, et al.
Bone Marrow Transplant
. 2021 May;
56(9):2319.
PMID: 34017072
No abstract available.
9.
Percival M, Wang H, Zhang M, Saber W, de Lima M, Litzow M, et al.
Bone Marrow Transplant
. 2021 Apr;
56(9):2108-2117.
PMID: 33864019
Acute myeloid leukemia (AML) patients often undergo allogeneic hematopoietic cell transplantation (alloHCT) in first complete remission (CR). We examined the effect of depth of clinical response, including incomplete count recovery...
10.
Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, et al.
Leukemia
. 2021 Mar;
35(6):1828.
PMID: 33782538
No abstract available.